PT  - JOURNAL ARTICLE
AU  - Yasamin Salimi
AU  - Daniel Domingo-Fernándéz
AU  - Carlos Bobis-Álvarez
AU  - Martin Hofmann-Apitius
AU  - for the Alzheimer’s Disease Neuroimaging Initiative
AU  - the Japanese Alzheimer’s Disease Neuroimaging Initiative
AU  - for the Aging Brain: Vasculature, Ischemia, and Behavior Study
AU  - the Alzheimer’s Disease Repository Without Borders Investigators
AU  - for the European Prevention of Alzheimer’s Disease (EPAD) Consortium
AU  - Colin Birkenbihl
TI  - ADataViewer: Exploring Semantically Harmonized Alzheimer’s Disease Cohort Datasets
AID  - 10.1101/2021.09.01.21262607
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.01.21262607
4099  - http://medrxiv.org/content/early/2021/09/14/2021.09.01.21262607.short
4100  - http://medrxiv.org/content/early/2021/09/14/2021.09.01.21262607.full
AB  - INTRODUCTION Currently, AD cohort datasets are difficult to find, lack across-cohort interoperability, and the content of the shared datasets often only becomes clear to third-party researchers once data access has been granted.METHODS We accessed and systematically investigated the content of 20 major AD cohort datasets on data-level. A medical professional and a data specialist manually curated and semantically harmonized the acquired datasets. We developed a platform that facilitates data exploration.RESULTS We present ADataViewer, an interactive platform that facilitates the exploration of 20 cohort datasets with respect to longitudinal follow-up, demographics, ethnoracial diversity, measured modalities, and statistical properties of individual variables. Additionally, we publish a variable mapping catalog harmonizing 1,196 variables across the 20 cohorts. The platform is available under https://adata.scai.fraunhofer.de/.DISCUSSION ADataViewer supports robust data-driven research by transparently displaying cohort dataset content and suggesting datasets suited for discovery and validation studies based on selected variables of interest.Competing Interest StatementDDF received salary from Enveda Biosciences and the company has no competing interests with the published results. The rest of the authors declare that they have no competing interests.Funding StatementThe research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EPAD grant agreement n°117536, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 826421, "TheVirtualBrain-Cloud".Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The respective data owners of the datasets used in this publication granted approval of the conducted experiments. A4: data access was granted after registration. ABVIB: approval was received to use the data for this project. ADNI: approval was received to use the data for this project. DOD-ADNI: approval was received to use the data for this project. AIBL: data access was granted after registration. ANM: data access was granted after registration. ARWIBO: data access was granted after registration. EDSD: data access was granted after registration. EMIF: data access was granted after registration. EPAD: data access was granted after registration. VASCULAR: data access was granted after registration. I-ADNI: data access was granted after registration. JADNI: data access was granted after registration. NACC: approval was received to use the data for this project. OASIS: data access was granted after registration. PREVENT-AD: data access was granted after registration. PharmaCog: data access was granted after registration. ROSMAP: data access was granted after registration. VITA: data access was granted after registration. WMH-AD: data access was granted after registration. The individual statement in the ethic oversight body is included in each individual study. For more details, we refer to the references in the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll reported results are available at https://adata.scai.fraunhofer.de. The datasets used in this publication are proprietary datasets owned by the respective data owners, access to the data can be requested using the information in https://adata.scai.fraunhofer.de/cohorts. https://adata.scai.fraunhofer.de